Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;28(4):767-780.
doi: 10.1007/s10741-022-10267-1. Epub 2022 Jul 25.

Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice

Affiliations
Review

Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice

Marta Cvijic et al. Heart Fail Rev. 2023 Jul.

Abstract

Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) was recently recognised as a distinct clinical entity. Although guideline diagnostic criteria for HFmrEF are well defined, there is substantial variation in clinical characteristics, pathophysiology and prognosis of this group of patients. The heterogeneity in clinical presentations of HFmrEF arises from diverse patients' risk factors, coexisting comorbidities, which modify clinical signs and symptoms, and stage of the disease. On the other hand, HFmrEF shares common clinical features with other HF subgroups. However, the knowledge about the mechanisms and therapeutic approaches in HFmrEF is far from being completely understood. Therefore, HFmrEF represents one of the most intriguing areas of heart failure research. The aim of this review is therefore to highlight the diagnostic challenges in HFmrEF and to provide a constructive appraisal on the pathophysiology of HFmrEF, as well as to discuss the role of pharmacological and nonpharmacological treatment options in patients with HFmrEF.

Keywords: Diagnosis; Heart failure with mildly reduced ejection fraction; Pathophysiology; Treatment.

PubMed Disclaimer

References

    1. Savarese G, Lund LH (2017) Global public health burden of heart failure. Card Fail Rev 03:7–11 - DOI
    1. Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200 - PubMed - DOI
    1. Lund LH, Claggett B, Liu J et al (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:1230–1239 - PubMed - DOI
    1. Chioncel O, Lainscak M, Seferovic PM et al (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1574–1585 - PubMed - DOI
    1. Koh AS, Tay WT, Teng THK et al (2017) A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 19:1624–1634 - PubMed - DOI

LinkOut - more resources